首页> 外文期刊>Journal of thrombosis and haemostasis: JTH >High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events.
【24h】

High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events.

机译:用基于聚集的环氧合酶-1抑制敏感性血小板功能试验测得的高阿斯匹林血小板反应性与动脉粥样硬化血栓形成事件的发生有关。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: High on-aspirin platelet reactivity (HAPR) is associated with atherothrombotic events following percutaneous coronary intervention (PCI). The aim of the present study was to identify the platelet function test sensitive for platelet cyclooxygenase-1 inhibition that best predicts atherothrombotic events. METHODS AND RESULTS: Nine hundred and fifty-one consecutive patients on dual antiplatelet therapy undergoing elective PCI were enrolled. On-aspirin platelet reactivity was measured in parallel by arachidonic acid (AA)-induced light transmittance aggregometry (AA-induced LTA), the VerifyNow(R) Aspirin Assay (VerifyNow(R) Aspirin Assay), the arachidonic acid prestimulated IMPACT-R (IMPACT-R AA) and the PFA-100 collagen/epinephrine cartridge (PFA COL/EPI). Cut-offs for HAPR were established by receiver-operator characteristic curve analysis. At 1-year follow-up, the composite of all-cause death, non-fatal acute myocardial infarction, stent thrombosis and ischemic stroke occurred more frequently in patients with HAPR when assessed by LTA [10.1% vs. 6.0%, P=0.020 (n=925)] and VerifyNow((R)) [13.3% vs. 5.9%, P=0.015 (n=422)]. The VerifyNow((R)) ASA assay (AUC=0.78) and, to a lesser extent, AA-induced LTA (AUC=0.73) added significantly to a model consisting of clinical and procedural risk factors in predicting atherothrombotic events. In contrast, the IMPACT-R (n=791) and the PFA Collagen/Epinephrine (n=719) were unable to discriminate between patients with and without primary endpoint at 1-year follow-up. None of the platelet function tests was able to identify patients at risk for bleeding. CONCLUSIONS: AA-induced LTA and the VerifyNow((R)) ASA test were able to identify aspirin-treated patients undergoing PCI with stenting at risk for atherothrombotic events. The VerifyNow((R)) Aspirin Assay had the highest predictive accuracy. None of the tests was able to identify patients at higher risk of bleeding.
机译:背景:阿司匹林的高血小板反应性(HAPR)与经皮冠状动脉介入治疗(PCI)后的血栓形成事件有关。本研究的目的是确定对血小板环加氧酶-1抑制敏感的血小板功能测试,以最佳预测动脉粥样硬化血栓形成事件。方法和结果:951例接受双重抗血小板治疗的行选择性PCI的患者。通过花生四烯酸(AA)诱导的光透射聚集法(AA诱导的LTA),VerifyNow®阿司匹林测定(VerifyNow®Aspirin测定),花生四烯酸预先刺激的IMPACT-R平行测定阿司匹林的血小板反应性(IMPACT-RA)和PFA-100胶原蛋白/肾上腺素药筒(PFA COL / EPI)。通过接受者-操作者特征曲线分析确定了HAPR的临界值。在1年的随访中,经LTA评估,HAPR患者全因死亡,非致命性急性心肌梗死,支架血栓形成和缺血性中风的发生率更高[10.1%vs. 6.0%,P = 0.020 (n = 925)]和​​VerifyNow(R)[13.3%vs. 5.9%,P = 0.015(n = 422)]。 ASA测定法VerifyNow(AUC = 0.78),以及在较小程度上,AA诱导的LTA(AUC = 0.73)显着增加了由临床和程序风险因素组成的模型的预测动脉粥样硬化血栓形成事件。相反,在1年的随访中,IMPACT-R(n = 791)和PFA胶原/肾上腺素(n = 719)无法区分主要终点与否的患者。血小板功能测试均无法识别有出血风险的患者。结论:AA诱导的LTA和ASA的VerifyNow测试能够鉴别出接受阿司匹林治疗的接受PCI支架置入术且有发生血栓形成事件的患者。 VerifyNow(R)阿司匹林测定法具有最高的预测准确性。没有一项测试能够确定出血风险较高的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号